Meropenem Mechanism of Action
Meropenem exerts its bactericidal effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), ultimately leading to cell lysis. 1
Molecular Mechanism
Meropenem penetrates the cell wall of most gram-positive and gram-negative bacteria to reach its target PBPs. Specifically, it binds to:
- PBPs 2,3, and 4 in Escherichia coli and Pseudomonas aeruginosa
- PBPs 1,2, and 4 in Staphylococcus aureus 1
By binding to these essential PBPs, meropenem disrupts the transpeptidation step of peptidoglycan synthesis, which is critical for maintaining bacterial cell wall integrity. This disruption leads to cell wall weakening and eventual bacterial cell death.
Bactericidal Activity
Bactericidal concentrations are typically 1-2 times the bacteriostatic concentrations, with the notable exception of Listeria monocytogenes, against which lethal activity is not observed 1. The bactericidal effect is defined as a 3 log₁₀ reduction in cell counts within 12-24 hours.
Structural Advantages
Meropenem possesses a 1-beta-methyl group on the carbapenem moiety that confers stability against human dehydropeptidase-I (DHP-I), unlike imipenem which requires co-administration with cilastatin 2, 3. This structural feature allows meropenem to be administered without an enzyme inhibitor.
Resistance to Beta-Lactamases
Meropenem demonstrates remarkable stability against most serine-based beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and AmpC enzymes 4, 5. This stability explains its broad spectrum of activity and effectiveness against many resistant organisms. However, it remains susceptible to:
- Carbapenemases (Class A, including KPC)
- Metallo-beta-lactamases (Class B, including NDM, VIM, IMP)
- OXA-48-like enzymes (Class D) 6
Clinical Implications
The pharmacodynamic parameter that best correlates with efficacy is the percentage of time that unbound plasma concentration exceeds the MIC of the infecting organism 1. This time-dependent killing characteristic guides dosing strategies, particularly in critically ill patients where maintaining concentrations above the MIC throughout the dosing interval is crucial for optimal outcomes.
Meropenem does not have activity against methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE) 1, which is an important limitation to consider when selecting empiric therapy.